Literature DB >> 35874288

Role of prostate stem cells and treatment strategies in benign prostate hyperplasia.

Kalyan J Gangavarapu1, Peter F Jowdy2,3, Barbara A Foster1, Wendy J Huss2,4.   

Abstract

Benign prostate hyperplasia (BPH) is a progressive disease with a direct correlation between incidence and age. Since the treatment and management of BPH involve harmful side effects and decreased quality of life for the patient, the primary focus of research should be to find better and longer-lasting therapeutic options. The mechanisms regulating prostate stem cells in development can be exploited to decrease prostate growth. BPH is defined as the overgrowth of the prostate, and BPH is often diagnosed when lower urinary tract symptoms (LUTS) of urine storage or voiding symptoms cause patients to seek treatment. While multiple factors are involved in the hyperplastic growth of the stromal and epithelial compartments of the prostate, the clonal proliferation of stem cells is considered one of the main reasons for BPH initiation and regrowth of the prostate after therapies for BPH fail. Several theories explain possible reasons for the involvement of stem cells in the development, progression, and pathogenesis of BPH. The aim of the current review is to discuss current literature on the fundamentals of prostate development and the role of stem cells in BPH. This review examines the rationale for the hypothesis that unregulated stem cell properties can lead to BPH and therapeutic targeting of stem cells may reduce treatment-related side effects and prevent the regrowth of the prostate. AJCEU
Copyright © 2022.

Entities:  

Keywords:  BPH; Prostate; androgen; stem cells

Year:  2022        PMID: 35874288      PMCID: PMC9301063     

Source DB:  PubMed          Journal:  Am J Clin Exp Urol        ISSN: 2330-1910


  139 in total

1.  Enhanced targeting of prostate cancer-initiating cells by salinomycin-encapsulated lipid-PLGA nanoparticles linked with CD44 antibodies.

Authors:  Jun Wei; Jin Sun; Yu Liu
Journal:  Oncol Lett       Date:  2019-02-19       Impact factor: 2.967

2.  Differentiation of the ductal epithelium and smooth muscle in the prostate gland are regulated by the Notch/PTEN-dependent mechanism.

Authors:  Xinyu Wu; Kun Xu; Lixia Zhang; Yan Deng; Peng Lee; Ellen Shapiro; Marie Monaco; Helen P Makarenkova; Juan Li; Herbert Lepor; Irina Grishina
Journal:  Dev Biol       Date:  2011-05-20       Impact factor: 3.582

3.  Activation of programmed cell death in the rat ventral prostate after castration.

Authors:  N Kyprianou; J T Isaacs
Journal:  Endocrinology       Date:  1988-02       Impact factor: 4.736

4.  Differential expression of keratins in the basal and luminal compartments of rat prostatic epithelium during degeneration and regeneration.

Authors:  A P Verhagen; T W Aalders; F C Ramaekers; F M Debruyne; J A Schalken
Journal:  Prostate       Date:  1988       Impact factor: 4.104

5.  Essential role for estrogen receptor beta in stromal-epithelial regulation of prostatic hyperplasia.

Authors:  Stephen J McPherson; Stuart J Ellem; Evan R Simpson; Vladimir Patchev; Karl-Heinrich Fritzemeier; Gail P Risbridger
Journal:  Endocrinology       Date:  2006-10-26       Impact factor: 4.736

6.  The connective tissue framework in the normal prostate, BPH and prostate cancer: analysis by scanning electron microscopy after cellular digestion.

Authors:  C Morrison; J Thornhill; E Gaffney
Journal:  Urol Res       Date:  2000-10

Review 7.  Diethylstilbestrol revisited: a review of the long-term health effects.

Authors:  R M Giusti; K Iwamoto; E E Hatch
Journal:  Ann Intern Med       Date:  1995-05-15       Impact factor: 25.391

8.  Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist.

Authors:  Ferenc G Rick; Andrew Abi-Chaker; Luca Szalontay; Roberto Perez; Miklos Jaszberenyi; Arumugam R Jayakumar; Nagarajarao Shamaladevi; Karoly Szepeshazi; Irving Vidaurre; Gabor Halmos; Awtar Krishan; Norman L Block; Andrew V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-28       Impact factor: 11.205

9.  Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial.

Authors:  Roger S Kirby; Claus Roehrborn; Peter Boyle; Georg Bartsch; Alain Jardin; Margaret M Cary; Michael Sweeney; Eric B Grossman
Journal:  Urology       Date:  2003-01       Impact factor: 2.649

10.  IL-1 induces IGF-dependent epithelial proliferation in prostate development and reactive hyperplasia.

Authors:  Travis J Jerde; Wade Bushman
Journal:  Sci Signal       Date:  2009-09-01       Impact factor: 8.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.